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Introduction
In 2012, there were 446,800 new cases of colorectal 
carcinoma (CRC) in Europe (1). Metastatic disease developed 
mostly within 3 years (2) in approximately 50% of cases: 
the first site of distant relapse was the liver, followed by the 
lung. Patients affected by metastatic CRC experienced a 
poor prognosis. Whenever feasible, surgery was considered 
an effective therapeutic option, with reported 5-year overall 
survival (OS) rates after radical resection ranging from 41% 
to 68% (3,4).
The unconfirmed predictors of survival, the lack of large 
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randomized trial and the undefined role of metastasectomy 
remained the unsolved problem in the management of 
patients with pulmonary metastasis (MTS) of CRC (5).
The purpose of the study was to evaluate the efficacy and 
the feasibility of lung metastasectomy in colorectal cancer 
(CRC) in our institution. Moreover, we aimed at exploring 
prognostic factors for survival and evaluating survival 
pattern in patients submitted to re-resections. 
Methods 
We included all consecutive patients who underwent lung 
metastectomy for pulmonary metastases from CRC at 
Department of Thoracic Surgery, University of Torino, 
Italy—from 2004 to 2012. Data were retrospective collected 
from the surgical registry of our Department. Follow-up 
(FU) data were acquired by routine visits, telephone contacts 
or from administrative data (outpatient regional registry). 
FU was completed over July 2014. Our Institutional 
Review Board approved the study. Inclusion criteria for 
lung metastasectomy comprised locally controlled primary 
CRC, no evidence of extra-thoracic lesions excluding 
hepatic metastases, single or multiple pulmonary nodules 
suitable for a radical resection. Stage of primary CRC was 
assigned according to the Union Internationale Contre 
le Cancer (UICC) staging system. Pre-operative patients 
assessment included clinical examination, blood tests, 
electrocardiogram, standard chest radiograph, contrast 
enhanced computed tomography (CT) scan of the chest and 
abdomen and positron emission tomography (PET) whole-
body scan. Pulmonary function tests with diffusion capacity 
and arterial blood gas analysis were also performed.
Type of surgical approach was selected according 
to the number, the location and the la laterality of the 
lesions; usually muscle-sparring axillary thoracotomy 
was the access of choice. In case of synchronous bilateral 
lesions, the surgical timing was tailored on each patient’s 
characteristic: patient with high number of metastases, 
larger lesions, old age or with poor pulmonary capacity was 
operated sequentially, at distance of one month. Complete 
palpation of the lung was performed in all the cases, except 
in case of thoracoscopic procedure. Wedge resection was 
accomplished to treat peripherally located pulmonary 
nodules; anatomical resections (segmentectomy or 
lobectomy) were achieved in case of multiple nodules in the 
same pulmonary segment or lobe, large size of the tumor 
or in case of a lesion located deeply in the parenchyma. 
Surgery was defined as radical (R0) when a complete 
tumor resection was accomplished, incomplete in case of 
microscopically (R1) or macroscopically (R2) residuals. 
Lymph node assessment included multiple biopsies of 
suspicious pulmonary and mediastinal lymph node.
Data variables and outcomes
Primary outcome was OS, calculated from the date of 
intervention to the date of death from any cause. Surviving 
patients were censored on the date of last FU. If bilateral 
resections were accomplished, outcomes were calculated from 
the date of the first surgery and resections were calculated as 
a single metastasectomy. Perioperative mortality was defined 
as any death occurred within 30 days from surgery: these 
events were included in the survival analysis.
According to literature, the following prognostic 
factors were collected: sex, gender, Eastern Cooperative 
Oncology Group (ECOG) performance status, Charlson 
Comorbidity Index (CCI) (age-adjusted), disease-free 
interval (DFI), primary tumor TNM stage, pre-thoracic 
surgery carcinoembryonic antigen (CEA) level, previous 
MTS in other sites, MTS number, metastases distribution, 
type of surgical resection, maximum lung MTS size, lymph-
nodal involvement, resection status, adjuvant therapy after 
lung intervention.
DFI was defined as the time period between curative 
primary CRC surgery and metastasectomy.
Secondary analysis was performed to define the 
progression free survival (PFS), calculated from the date 
of intervention to the date of local or distant recurrence or 
death from any cause.
Survival in case of re-intervention and correlation 
between pre-operative PET scan lymph-nodal status and 
pathological lymph-nodal involvement were also evaluated.
Statistical analysis
Time-to-event variables were estimated using the Kaplan-
Meier method and compared using log-rank test. Possible 
predictors of survival were investigated using the Cox 
proportional hazards regression model. Hazard ratios (HR) 
and the corresponding 95% confidence intervals (95% CI) 
were provided. The results of the univariate analyses were 
not reported in the text, in order not to lengthen the 
paper. The following predictors were included in the final 
multivariate model: advanced primary CRC pTNM stage 
(III–IV), age-adjusted CCI (as continuous variable), number 
of MTS (2–4 vs. 1 and ≥5 vs. 1), lung MTS size (≥20 mm), 
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lymph-nodal involvement, incomplete surgery (R1-2), DFI 
(≥30 months) and adjuvant therapy after lung resection. 
All statistical analyses were performed using SAS (version 
8.2) and STATA (version 12.1).
Results
One-hundred eighty-eight consecutive cases were included 
in the final analysis. Population’s demographics and clinical, 
surgical and pathologic characteristics are showed in Table 1.
Most of patients were male (109, 58%), median age at 
surgery was 66 years [interquartile range (IQR), 58–72 years]. 
Most patients had an ECOG performance status at surgery of 
0–1 (159, 85%) and an age-adjusted CCI value less than 2 (82, 
44%). Thirty-three (18%) patients had a previous malignant 
solid tumor, other than primary CRC.
Concerning primary CRC, all patients underwent a 
radical resection of the primary tumor and most of them 
had an advanced stage cancer (III–IV; 108, 62%). After 
colon resection, 110 patients (63%) received adjuvant 
chemotherapy, with varied drugs regimens according to the 
different oncological team, which followed the patients. 
In sixty-one patients (32%) a previous MTS was observed 
before the lung lesion: 54/61 were liver metastases (88%). 
All metastases were radically treated before thoracic surgery. 
Median disease-free interval (DFI) was 30 months (IQR, 
15–48 months).
One-hundred fifty-two patients (81%) was treated 
for unilateral lung metastases and 53/152 patients (35%) 
had multiple pulmonary nodules (range, 2–11). Thirty-
six patients had multiple bilateral lesions: two patients 
were operated through a complete sternotomy, 34 (94%) 
Table 1 Population’s demographics and clinical, surgical and 
pathologic characteristics
Demographics and characteristics n %
Gender (male) 109 58
Age (years) (median; IQRa) 66 58–72
ECOG (n=188)
0 119 63
1 40 22
2 24 13
3 5 2
CCI (n=188)
≤2 82 44
3–5 78 41
>5 28 15
CRCb pTNM stages (n=175)
1 18 10
2 49 28
3 74 42
4 34 20
DFI (months) (median; IQR) 30 15–48
Previous MTSc 61 32
Liver 54 88
MTS size (mm) (median; IQR) 17 12–27
Number of MTS (n=187)
1 99 53
2–4 72 38
≥5 16 9
Surgery (n=188) 
Combined 5 3
Lobectomy 38 20
Pneumonectomy 1 1
Segmentectomy 16 9
Wedge resection 128 68
Resection status (n=187)
R0 173 92
R1 13 7
R2 1 1
Table 1 (continued)
Table 1 (continued)
Demographics and characteristics n %
Lymph node involvement (n=187)
N+ 16 8
N0 149 80
Nx 22 12
Preoperative treatment 27 14
Adjuvant treatment (n=174) 110 63
a, interquartile range; b, colorectal cancer; c, metastasis; d, 
carcinoembryonic antigen eastern; ECOG, Eastern Cooperative 
Oncology Group; DFI, disease-free interval; CCI, Charlson 
Comorbidity Index.
1767Journal of Thoracic Disease, Vol 8, No 7 July 2016
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016;8(7):1764-1771jtd.amegroups.com
through a two open axillary thoracotomy. Five patients 
were submitted to thoracoscopic resections (3%). In most 
of the cases wedge resections were achieved (128, 68%), 
in the remaining patients anatomical resection (29%; 38 
lobectomy, 16 segmentectomy and 1 pneumonectomy) 
or combined resection (5, 3%—e.g., anatomical resection 
+ wedge resection) were performed. Median metastases 
size was 17 mm (IQR, 12–27 mm). A radical resection was 
accomplished in 173 cases (92%) and lymphadenectomy 
was performed in 165 cases (88%): 16 patients (8%) had a 
histologically proved lymph-nodal involvement.
Five (2%) patients experienced a major complication: 2 
contralateral pneumothorax, 1 pneumonia, 1 haemothorax 
and 1 heart failure. One perioperative death was observed.
One-hundred twenty-two patients (65%) received 
a  complementary treatment:  110 (63%) adjuvant 
chemotherapy and 27 (14%) preoperative chemotherapy 
(14 patients both regimens). 
In 179 patients (95%) PET whole-body scan was 
assessed: lymph node resulted positive in 10 patients. 
One-hundred thirty-seven node metastases were correct 
evaluated by PET (accuracy 86%): positive predictive 
value and negative predictive value were 20% and 91%, 
respectively.
Predictors and outcome
The median FU was 45 months (IQR, 30–69 months) and 
at the end of the study period, 77 patients died (41%). In 
the analyzed population, overall 2- and 5-year survival were 
80% (95% CI: 73–85%) and 53% (95% CI: 44–60%), 
respectively (Figure S1). 
At the end of the study period, 175 patients were 
evaluable for relapse and 90 (51%) relapses were observed. 
After a R0 resection, PFS rates at 2- and 5-year were 
54% (95% CI: 46–62%) and 33% (95% CI: 25–42%), 
respectively (Figure S2). 
Thirty-nine relapsed patients (41%) were re-submitted 
to lung metastasectomy: 35 (90%) were re-operated once 
and 4 twice. Figure 1 showed survival in the cohort of 
patients submitted to re-intervention: 2- and 5-year survival 
after re-resection were 79% (95% CI: 63–89%) and 49% 
(95% CI: 31–65%), respectively. 
Table 2  i l lustrated the results of univariate and 
multivariate models. At univariate analysis number of 
resected MTS ≥5 (Figure S3, P=0.021), high CCI (P=0.077) 
and lymph nodal involvement (Figure 2, P<0.0001) 
negatively influence survival. Moreover, patients with 
multiple metastases submitted to adjuvant treatment showed 
a slight better survival (P=0.03, Figure 3).
Multivariable adjusted analysis indicated that primary 
CRC pathological TNM stages (P=0.019), number of 
resected MTS ≥5 (P=0.009) and lymph nodal involvement 
(P<0.0001) are independent predictors of poor prognosis.
Discussion 
The first objective of this study was to evaluate the efficacy 
and feasibility of lung metastasectomy in CRC and factors 
of prognostic relevance for survival in these patients. 
Moreover, we aimed to define survival pattern in patients 
submitted to re-resection after lung recurrence. 
The results of our study suggest that (I) primary CRC 
TNM stage, more than five resected MTS and lymph 
nodal involvement demonstrated to be independent 
predictors of survival after surgical resection; (II) survival 
after surgery remains comforting up to four resected 
MTS; (III) patients submitted to re-intervention for lung 
relapses showed a satisfactory prognosis; (IV) absence 
of pathological uptake at a preoperative PET scan was 
not significantly associated with absence of lymph node 
involvement; (V) adjuvant chemotherapy seems to have a 
positive effect on survival in patients affected by multiple 
metastases.
Prerequisites for potentially curative lung metastasectomy, 
first described by Thomford in 1965 (6) are widely applied 
today, with minor modification: (I) metastases resection 
deemed to be technically feasible; (II) acceptable surgical risk; 
(III) control of the primary tumor; and (IV) no evidence of 
extra-thoracic MTS. However, many issues on timing and 
Figure 1 Survival according to re-intervention.
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proper indication to surgery remained opened and discussed 
worldwide. Actually, it is undeniable that patients undergoing 
surgery and redo surgery are exposed to post-operative 
complications. Nevertheless, in our experience morbidity 
is low (2%) and related with more extended resection (e.g., 
pneumonectomy, combined resection), in line with the data 
reported in other lung metastasectomy series (0–2.5%) (4,7).
In the subset of patients eligible for resection, 5-year 
OSs range from 25% to 68% (3). The identification of 
predictive factors in this sub-group is essential to select 
those patients who really benefit from surgery and to tailor 
pre- and/or post-operative strategy. To date, available 
Table 2 Univariate and multivariate analysis of prognostic factors after lung metastasectomy (Cox proportional hazards regression model)
Factors 
Univariate models Multivariate model
Hazard ratio P
95% CI
Hazard ratio P
95% CI
Upper Lower Upper Lower
CRCa pTNM stage (I–II as reference)
III–IV 1.456 0.134 0.891 2.382 1.906 0.019 1.112 3.268
Charlson Comorbidity Index (age-adjusted) 1.068 0.077 0.993 1.150 1.071 0.119 0.982 1.168
Number of MTSb (1 as reference)
2–4 0.991 0.971 0.607 1.619 0.886 0.645 0.531 1.480
≥5 2.365 0.021 1.138 4.913 2.748 0.0092 1.285 5.876
MTS size (>20 mm) 1.326 0.283 0.792 2.219 1.171 0.575 0.674 2.033
Lymph node involvement (N0 as reference)
N+ 3.633 <0.0001 1.957 6.745 4.866 <0.0001 2.370 9.992
Nx 1.244 0.516 0.644 2.405 1.254 0.532 0.617 2.547
Resection status (R0 as reference) 1.446 0.325 0.694 3.013 0.990 0.982 0.435 2.257
DFI (>30 months)c 1.080 0.736 0.689 1.694 1.227 0.401 0.762 1.974
Adjuvant chemotherapy (yes) 1.034 0.885 0.654 1.636 0.674 0.147 0.396 1.148
a, colorectal cancer; b, metastasis; c, disease free interval. CI, confidence interval.
Figure 2 Survival according to lymph node involvement.
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
C
um
ul
at
iv
e 
in
ci
de
nc
e
Survival according to lymph node lnvolvement
At risk:
60483612 24
Months
0
No 149 145 113 77 52 36
Yes 16 11 6 5 2 1
No
Yes
Figure 3 Survival according to adjuvant treatment (in case of 
multiple metastases).
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
C
um
ul
at
iv
e 
in
ci
de
nc
e
Survival according to adjuvant treatment
At risk:
60483612 24
Months
0
No 26 21 14 6 4 2
Yes 54 52 42 32 20 13
No
Yes
1769Journal of Thoracic Disease, Vol 8, No 7 July 2016
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016;8(7):1764-1771jtd.amegroups.com
evidence is still based on single center experience, often 
reported series over a long period of time, and few 
systematic reviews. Consequently, predictive factors 
remained controversial. Hopefully, some clarification 
is expected from a prospective randomized trial (8), 
set up to investigate the efficacy of “active monitoring 
with pulmonary metastasectomy” in patients with lung 
metastases from CRC.
Previous studies including our series show the prognostic 
significance of hilar and/or mediastinal lymph node 
involvement (4,7,9-11). Even if the role of mediastinal 
systematic nodal dissection remains unclear (12), our results 
and the bulk of previous literature supported the lymph 
node sampling practice. 
Fluorodeoxyglucose-labeled positron emiss ion 
tomography (FDG-PET) allows the detection of intra- and 
extrathoracic tumor deposits. Pastorino at al. illustrated 
the importance of PET in the preoperative mediastinal 
and hilar staging of pulmonary metastases, reporting 
a high sensitivity and accuracy (100% and 96%) (13). 
Contrariwise, a recent study (14) reported a high rate of 
unexpected lymph node disease in resected lung MTS and 
emphasized the value of lymph node sampling. In our series 
the positive predictive value of PET on detecting lymph 
nodal involvement results remarkably low (20%), even if 
negative predictive value remains high as expected (91%). In 
our opinion, these findings do not undervalue the value of 
the PET as pre-operative staging exam, but they underline 
the need to perform at least a selected lymph node sampling 
in order to eradicate a possible unidentified source of 
metastatic spreads and to allow a more personalized post-
operative treatments and FU.
In the present study as well as previously reported in 
literature (15,16), pathologic stage of primary CRC had 
a significant impact on survival. Nonetheless, there is no 
definite agreement on the value of its prognostic role: the 
majority of authors failed to confirm a correlation between 
primary tumor stage and survival (4,17).
Poor survival for patient with multiple MTS has been 
frequently reported in literature (18,19). In our institution, 
multiple resection of colorectal MTS is usually achieved 
when feasible: the results presented in this study indicated 
a similar survival from 1 to 4 resected metastases. In the 
recent years, some studies have documented a comparable 
comforting survival in oligometastatic patients (9-11,20,21), 
probably resulting from improvements in pre-operative 
se lect ion,  surgica l  techniques  and per ioperat ive 
management. Although this finding deserves future 
validation, the significant prognostic value of the presence 
of more than five metastases corroborates the importance of 
surgery in oligometastatic disease. 
Rate of relapses after resection of colorectal lung 
metastases is uncommonly reported in literature and 
remains discouraging high, ranging from 20% to 68% (4,7), 
with the lung as the commonest site of recurrence. In case 
of local relapses after lung metastasectomy, redo-surgery 
could be a reasonable therapeutic choice: in the last years, 
a number of reports in the literature documented a survival 
benefit after re-resection (7,10). In our experience, 5-year 
survival of patient submitted to repeat lung metastasectomy 
is encouraging (49%). Nevertheless, if only a highly selected 
subset of patients is eligible for pulmonary resection, re-
intervention results feasible exclusively in an even more 
restricted patient subset. For these reasons new randomized 
control trials are needed to determine the true benefits 
of re-resection, especially because, in this setting, surgery 
should be compared with alternative treatment regimens 
[i.e., radiofrequency ablation (RFA), stereotactic ablative 
radiation therapy (SABR)] (22). 
Finally, in our analysis, we observed an improved survival 
in patients with multiple metastases submitted to post-
operative chemotherapy vs. surgery alone. The impact of 
adjuvant chemotherapy after lung metastasectomy was 
investigated in few studies, demonstrating a protective 
effect of chemotherapy on survival (23). Recently, a pooled 
analysis of two randomized clinical trial evaluating adjuvant 
chemotherapy after resection of colorectal liver or lung 
metastases indicated a potential positive effect of post-
operative chemotherapy, but both studies were closed due 
to difficulties in patients’ enrolment and the benefit on OS 
remains undetermined (24). Future controlled clinical trials 
on adjuvant chemotherapy after lung metastasectomy are 
advisable, maybe focused on patients affected by multiple 
metastases.
Conclusions 
Patients operated and re-operated for lung metastases 
from CRCs show an encouraging survival. Our results 
indicate that primary CRC stage; number of MTS and 
lymph nodal involvement are strong prognostic factors. 
Prognosis after surgery remained comforting up to 4 
resected MTS. Furthermore, adjuvant chemotherapy seems 
to have a benefit on survival in patients affected by multiple 
metastases. Finally, precise pre-operative selection remains 
mandatory and according to the high rate of unidentified 
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lymph node involvement in pre-operative setting, lymph 
node sampling should be advisable for a correct staging.
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